Melanoma Breakthroughs and the Promise of Curative Therapy | Scott Schliebner

What happens when a treatment has the potential to cure disease rather than manage it for years?

Scott Schliebner returns to BioTalk Unzipped for a deeper discussion of rare disease clinical trials, gene therapy, cell therapy, cancer treatment, and one of the most difficult questions in modern medicine: how should potentially curative therapies be valued and made accessible?

Scott first expands on the operational complexity of rare disease studies, including patient recruitment, multidisciplinary care, and the importance of collaboration among stakeholders.

The conversation then examines how AI might help identify patients and analyze increasingly complex clinical datasets.

A major focus is the FDA approval of Iovance’s Amtagvi, discussed in the episode as the first T-cell therapy approved for a solid tumor. Scott, Gregory, and Chad examine what progress in melanoma might mean for the broader effort to bring cell therapies into solid tumors.

That leads to a larger discussion about gene and cell therapy economics. If a therapy can eliminate years of ongoing medical treatment, what should it cost? How should healthcare systems weigh upfront expense against long-term health and economic benefit?

The episode concludes with practical career advice for both early-career and experienced clinical-development professionals.

Chapters

00:21 - A collaborative approach to rare disease trials

03:32 - The role of AI in rare disease trials

06:11 - Success stories in rare disease development

11:34 - Expanding gene therapy to target multiple genes

16:56 - New News: FDA approval of Iovance's Amtagvi and the melanoma breakthrough

19:27 - Targeting solid tumors with cell therapy and expanding its potential

20:23 - How curative therapies could affect quality of life and healthcare costs

21:11 - Pricing and ethical challenges surrounding advanced therapies

22:37 - Lessons from curative treatments for hepatitis C

23:25 - The high bar for clinical development and regulatory standards

24:05 - Pricing considerations across cancer types and the possibility of cost-effective treatments

27:45 - Advice for young professionals entering clinical drug development

31:49 - Advice for established clinical professionals

33:21 - Scott’s hobbies and interests

Rare Givers

Learn more or donate:

https://www.raregivers.global/

Connect with Scott Schliebner

https://www.linkedin.com/in/scott-schliebner-1087789/

Connect with the hosts

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

New News

FDA approves first T-cell therapy for a solid tumor:

https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor

Image credits

Iovance: https://www.iovance.com/

FDA approval: https://www.tipranks.com/news/iovance-nasdaqiova-fda-approves-cell-therapy-stock-gains

Amtagvi: https://www.amtagvi.com/

#melanoma #raredisease #celltherapy #genetherapy #clinicaltrials #science